Pfizer has refused to comment on claims made by the Irish press it is investing €1 billion ($1 billion) in its Grange Castle biomanufacturing site. The 90-acre manufacturing site in Clondalkin in Dublin was opened in 2006 following a $2 billion investment by Wyeth (which Pfizer acquired in 2009). The site has benefitted from continual investments and expansion since, including a $40 million mRNA expansion to support the firm’s COVID-19 vaccine efforts. But now Pfizer could be ready to invest…

Triumvira will expand its autologous T-cell manufacturing network by placing its staff and tech within AmplifyBio’s facilities in South San Francisco, California. Within the cell therapy space, an ongoing topic of debate is whether to build an inhouse manufacturing network or use a contract development and manufacturing organization (CDMO). But for Triumvira Immunologics, a third option has been exercised: a pact for Triumvira to manufacture its own cell therapy candidates within a facility in South San Francisco run by contract…